TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: ICAM-1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Risk of developing symptomatic PAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: activity limitations
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Sustained unresponsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Desensitization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: OVA-specific IgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Self-mastery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean IGF‐I plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean daily nitrogen balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 5-year postsurgical survival
Endpoint domain: Mortality/survival
Primary endpoint: retained functional larynges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events in the genitourinary system
Endpoint domain: Adverse events/effects
Primary endpoint: Normal plasma creatinine (PCr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Low molecular weight (LMW) proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: clinical efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: adverse reaction rate
Endpoint domain: Adverse events/effects
Primary endpoint: Scores in the Buschke test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in wall motion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low reflow ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increment in CD4+ cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IRD measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RA thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: maximal isometric contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cerebral palsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Loss of endothelial cells in the central cornea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: take home baby rate
Endpoint domain: Mortality/survival
Primary endpoint: spontaneous abortion rates
Endpoint domain: Adverse events/effects
Primary endpoint: myeloperoxidase (MPO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: malondialdehyde (MDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glutathione peroxidase (GSH-Px)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SpHb accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: High activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: High exploration
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Area under the plasma concentration-time curve (AUC) of 3-keto-desogestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Side Effects of Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Body Image
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: week-48 ASDAS inactive disease achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: week-48 minimal disease activity achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in bone formation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in C‐telopeptide of type‐I collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: stone-free rate (SFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pruritus intensity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Xerosis improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful placement of cervical Foley catheters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to cervical dilation (3-6 cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: small-for-gestational-age birth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: number of women with hypertension disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Minimum local anesthetic concentration (MLAC) of levobupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: current knee pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy purchased from drinks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative AHI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: self-reported quit rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Duration of arytenoidectomies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Disease progression in Friedreich ataxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ambulatory systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic pressure rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean chest compression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correct hand positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: No-flow time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximal work capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean time taken for barrier
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time taken for completion of lamina dura
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardiac events at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: induction time of sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: propofol target‐controlled concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRBSI infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: CVC thrombosis rate
Endpoint domain: Adverse events/effects
Primary endpoint: Specificity of clinical nodes for diagnosis of pathological nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value of clinical nodes for diagnosis of pathological nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-enrollment rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increased activity in brain voxels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Infection frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Dyskinesias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain ratings improvement during activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with the procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite hypoglycemia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptomatic hypoglycemia events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of corneal oedema
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative central corneal thickness values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumour-free survival
Endpoint domain: Mortality/survival
Primary endpoint: CD8(+) cells elevation in the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-5 concentration in BAL fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 24-hour urinary excretion of 6 beta-hydroxycortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ratio of 6 beta-hydroxycortisol to 17-hydroxycorticosteroid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean pulmonary artery pressure (PAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Apgar scores at one minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for neonatal resuscitation and naloxone administration
Endpoint domain: Adverse events/effects
Primary endpoint: CRP pool size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRP fractional catabolic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRP production rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate spontaneous or assisted ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Observation of vocal cords with fiberoptic laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of nail lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall severity score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported therapy results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anesthesia costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Functional outcome assessed using Harris Hip Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Further surgery for periprosthetic fracture
Endpoint domain: Adverse events/effects
Primary endpoint: PANSS negative subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total diagnostic quality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Natural killer cytotoxicity of PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Red cell deformability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Functional outcomes at one year post-injury
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean albuminuria reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Solicited local adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Seroconversion against antigens A/H1N1, A/H3N2, and B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprotection against antigens A/H1N1, A/H3N2, and B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median hospitalization time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Late recurrence of pleural effusion
Endpoint domain: Adverse events/effects
Primary endpoint: Achieved spontaneous pleurodesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1RM (one-repetition maximum)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: RFD (rate of force development)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: BMD (bone mineral density) improvements at lumbar spine and total hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: subjective pruritus scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: erythema scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: desquamation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean improvement in functional level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in immune markers (TNF-alpha, IL-2, IL-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Probability of visual detection of TOF fade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of visual detection of DBS(3,3) fade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of visual detection of DBS(3,2) fade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in delirium severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional activity maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: current asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ever asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Success rate at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean values of MDE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of diaphragmatic ultrasound in predicting weaning failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Twenty-eight-day mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: safety and efficacy of DES and BMS with cortisone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total colonic fecal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dixon signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: T2-weighted signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ex vivo lipopolysaccharide-stimulated PGE2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urinary prostacyclin metabolite levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: fracture resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of procalcitonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of interleukin-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma AUC of fexofenadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tmax after jejunal application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extent of visual field loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of successful lumbar puncture (LP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in myocardial injury markers (e.g., troponin T, creatine kinase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Private cost associated with attendance for AAA screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Melanin index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: LN metastasis observed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Residual LNs in area ventral to right cervical RLN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Recurrence of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cardiac dysfunction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in MeanMaxPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in MaxMaxPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clitoral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Salivary anti-Pnc IgA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum plasma concentration of epinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects (transient pallor, tremor, anxiety, palpitations)
Endpoint domain: Adverse events/effects
Primary endpoint: NCEP LDL-C goals achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total cost of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of office visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: take rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: closure of the air-bone gap (ABG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immediate improvement in hearing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improvement in executive functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in figural memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in cognitive flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Descemet membrane detachment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean ECD (endothelial cell density)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual recovery time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 8 ft up and go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: knee extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Improvements of daytime functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Erythrocyte membrane DHA composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful pulpal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: septic shock incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: organ morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean global cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean composite cognitive function scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: urinary concentration of deoxypyridinoline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative FMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Relative VO2 peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in SDQ Emotional Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in Total Difficulties on SDQ
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing